Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles

1 Dec 2023

Abstract excerpt

Homologous recombination deficiency (HRD) is a predictive biomarker for poly(ADP-ribose) polymerase 1 inhibitor (PARPi) sensitivity. Routine HRD testing relies on identifying BRCA mutations, but additional HRD-positive patients can be identified by measuring genomic instability (GI), a consequence of HRD. However, the cost and complexity of available solutions hamper GI testing. We introduce a deep learning...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CRISPR and Genetic Engineering
Share to DNA Repair Mechanisms
Share to PARP inhibition in cancer therapy

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38118421
DOI: 10.1016/j.xcrm.2023.101344

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profilesPMID 38118421Read ↗

DirectHRD enables sensitive scar-based classification of homologous recombination deficiencySemantic proximity Read ↗

A deep learning approach for improved detection of homologous recombination deficiency from shallow genomic profilesSemantic proximity Read ↗

Detecting HRD in whole-genome and whole-exome sequenced breast and ovarian cancersSemantic proximity Read ↗

Validation of Genomic and Transcriptomic Models of Homologous Recombination Deficiency in a Real-World Pan-Cancer CohortSemantic proximity Read ↗

HRProfiler Detects Homologous Recombination Deficiency in Breast and Ovarian Cancers Using Whole-Genome and Whole-Exome Sequencing Data.Semantic proximity Read ↗

AI-Enabled Prediction of Homologous Recombination Deficiency from Histopathology ImagesSemantic proximity Read ↗

Whole-exome sequencing provides assessment of homologous recombination deficiency for identification of PARPi-responsive ovarian tumors.Semantic proximity Read ↗

Validation of genomic and transcriptomic models of homologous recombination deficiency in a real-world pan-cancer cohortSemantic proximity Read ↗

Direct prediction of Homologous Recombination Deficiency from routine histology in ten different tumor types with attention-based Multiple Instance Learning: a development and validation studySemantic proximity Read ↗

Comparative Assessment of Diagnostic Homologous Recombination Deficiency-Associated Mutational Signatures in Ovarian Cancer.Semantic proximity Read ↗

Unraveling Homologous Recombination Deficiency in Ovarian Cancer: A Review of Currently Available Testing PlatformsSemantic proximity Read ↗

Combination of<i>BRCA</i>deep targeted sequencing and shallow whole genome sequencing to detect homologous recombination deficiency in ovarian cancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.